PDF(Sci-hub)
Abstract：
BACKGROUND: Analysis of retinal microaneurysm turnover (MAT) has been previously shown to contribute to the identification of eyes at risk of developing clinically significant complications associated with diabetic retinopathy (DR). We propose to further characterize MAT as a predictive biomarker of DR progression and development of vision-threatening complications.
METHODS: 212 individuals with type 2 diabetes (T2D; ETDRS grades 20 and 35) were evaluated annually in a 5-year prospective, longitudinal study, by color fundus photography and optical coherence tomography. Endpoints were diabetic macular edema (DME) or proliferative retinopathy (PDR). MAT analysis included determination of MA formation and disappearance rates, automatically assessed using the RetMarkerDR®. Retinopathy severity progression was evaluated using step increases in ETDRS severity levels.
RESULTS: Of the 212 individuals, 172 completed the 5-year follow-up study or developed an endpoint (n = 27). MAT calculated at 1 year showed a significant difference between groups of endpoint developments (p = 0.018), particularly MA disappearance rate (p = 0.007). MAT also showed a significant difference between eyes with different ETDRS severity progression in the 5-year period (p = 0.035).
CONCLUSIONS: MAT is an indicator of the development of DME and/or PDR as well as of DR severity progression in T2D individuals with mild retinopathy.
METHODS: 212 individuals with type 2 diabetes (T2D; ETDRS grades 20 and 35) were evaluated annually in a 5-year prospective, longitudinal study, by color fundus photography and optical coherence tomography. Endpoints were diabetic macular edema (DME) or proliferative retinopathy (PDR). MAT analysis included determination of MA formation and disappearance rates, automatically assessed using the RetMarkerDR®. Retinopathy severity progression was evaluated using step increases in ETDRS severity levels.
RESULTS: Of the 212 individuals, 172 completed the 5-year follow-up study or developed an endpoint (n = 27). MAT calculated at 1 year showed a significant difference between groups of endpoint developments (p = 0.018), particularly MA disappearance rate (p = 0.007). MAT also showed a significant difference between eyes with different ETDRS severity progression in the 5-year period (p = 0.035).
CONCLUSIONS: MAT is an indicator of the development of DME and/or PDR as well as of DR severity progression in T2D individuals with mild retinopathy.
摘要：
背景：视网膜微动脉瘤转换（MAT）的分析先前已被证明有助于识别有发生与糖尿病性视网膜病变（DR）相关的临床重大并发症的风险的眼睛。我们建议进一步表征MAT作为DR进展和视力威胁并发症发展的预测生物标志物。
方法：每年对212名2型糖尿病患者（T2D;ETDRS等级20和35）进行5年前瞻性评估，纵向研究，通过彩色眼底照相和光学相干层析成像。终点为糖尿病性黄斑水肿(DME)或增生性视网膜病变(PDR)。MAT分析包括MA形成和消失率的测定，使用RetMarkerDR®自动评估。使用ETDRS严重程度水平的逐步增加来评估视网膜病变严重程度的进展。
结果：在212个人中，172完成了5年的随访研究或确定了终点（n=27）。在1年计算的MAT显示终点发展组之间存在显着差异（p=0.018），特别是MA消失率（p=0.007）。MAT还显示在5年期间具有不同ETDRS严重程度进展的眼睛之间的显著差异(p=0.035)。
结论：MAT是轻度视网膜病变的T2D个体中DME和/或PDR发展以及DR严重程度进展的指标。
方法：每年对212名2型糖尿病患者（T2D;ETDRS等级20和35）进行5年前瞻性评估，纵向研究，通过彩色眼底照相和光学相干层析成像。终点为糖尿病性黄斑水肿(DME)或增生性视网膜病变(PDR)。MAT分析包括MA形成和消失率的测定，使用RetMarkerDR®自动评估。使用ETDRS严重程度水平的逐步增加来评估视网膜病变严重程度的进展。
结果：在212个人中，172完成了5年的随访研究或确定了终点（n=27）。在1年计算的MAT显示终点发展组之间存在显着差异（p=0.018），特别是MA消失率（p=0.007）。MAT还显示在5年期间具有不同ETDRS严重程度进展的眼睛之间的显著差异(p=0.035)。
结论：MAT是轻度视网膜病变的T2D个体中DME和/或PDR发展以及DR严重程度进展的指标。
